ADAM17 study reveals a cellular defense against HIV-1
Published in Diseases!, Immunology, Journals.
Published October 18, 2026.
A study published in Nature Communications on October 17 identifies an antiviral role for ADAM17, a human protein already known for its involvement in inflammatory signaling.
The researchers report that ADAM17 limits HIV-1 infectivity in laboratory experiments, with effects observed across laboratory-adapted viruses and primary isolates. The work included cultured CD4-positive T cells and primary human lymphocytes.
The findings connect this protective effect to the processing of viral envelope proteins and show that HIV-1 can counteract the cellular defense. This expands understanding of the interactions between host-cell biology and viral replication.
In an accompanying research commentary, the authors raise a further question: whether this interaction also contributes to persistent inflammation associated with HIV infection. They emphasize that this possible connection requires additional investigation.
Limits: These findings describe a cellular mechanism, not a demonstrated treatment or cure. They do not show that changing ADAM17 activity is safe or beneficial in patients. The research article is an early, peer-reviewed accepted version and remains subject to editorial changes.
Sources: Li and colleagues, Nature Communications, October 17, 2026; authors’ research commentary.